-- Shionogi & Co (TYO:4507) will absorb its wholly owned subsidiary Torii Pharmaceutical through an absorption-type merger effective April 1, 2027, as it moves to strengthen integration and decision-making, according to a Monday filing on the Tokyo Stock Exchange.
The companies signed the merger agreement on April 27 following board approval the same day.
Shionogi will remain the surviving entity, while Torii Pharmaceutical will be dissolved, with no new shares or cash consideration issued as part of the transaction.
The company said the merger will deepen collaboration and enhance synergies, particularly in therapeutic areas such as allergy and dermatology.